✦ LIBER ✦

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

✍ Scribed by Michel Ducreux; David Malka; Jean Mendiboure; Pierre-Luc Etienne; Patrick Texereau; Dominique Auby; Philippe Rougier; Mohamed Gasmi; Marine Castaing; Moncef Abbas; Pierre Michel; Dany Gargot; Ahmed Azzedine; Catherine Lombard-Bohas; Patrick Geoffroy; Bernard Denis; Jean-Pierre Pignon; Laurent Bedenne; Olivier Bouché

Book ID: 117785740
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 331 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70199-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab in combination with chemothe

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

✍ Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Aki 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 332 KB

Intermittent versus continuous oxaliplat

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

✍ Richard A Adams; Angela M Meade; Matthew T Seymour; Richard H Wilson; Ayman Madi 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 420 KB

Addition of cetuximab to oxaliplatin-bas

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

✍ Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 364 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

Concomitant chemoradiotherapy versus acc

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

✍ Jean Bourhis; Christian Sire; Pierre Graff; Vincent Grégoire; Philippe Maingon; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 332 KB

Intensified chemotherapy with ACVBP plus

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

✍ Christian Récher; Bertrand Coiffier; Corinne Haioun; Thierry Jo Molina; Christop 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 298 KB